Praxis Investment Management Inc. Makes New $426,000 Investment in IQVIA Holdings Inc. $IQV

Praxis Investment Management Inc. acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 2,245 shares of the medical research company’s stock, valued at approximately $426,000.

Other institutional investors have also made changes to their positions in the company. Artisan Partners Limited Partnership acquired a new stake in IQVIA during the 2nd quarter valued at $515,772,000. Norges Bank bought a new position in shares of IQVIA in the second quarter valued at about $270,160,000. AQR Capital Management LLC lifted its stake in shares of IQVIA by 130.2% during the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock worth $245,099,000 after buying an additional 879,701 shares during the last quarter. Laurel Wealth Advisors LLC boosted its holdings in shares of IQVIA by 15,755.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 779,598 shares of the medical research company’s stock worth $122,857,000 after buying an additional 774,681 shares during the period. Finally, Nordea Investment Management AB grew its stake in IQVIA by 41.7% in the 2nd quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after buying an additional 606,391 shares during the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at IQVIA

In other IQVIA news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the transaction, the insider directly owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This trade represents a 12.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.60% of the stock is owned by insiders.

IQVIA Price Performance

IQVIA stock opened at $223.71 on Tuesday. The firm has a market cap of $38.10 billion, a PE ratio of 30.69, a price-to-earnings-growth ratio of 2.49 and a beta of 1.37. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. The stock’s fifty day moving average price is $217.39 and its two-hundred day moving average price is $190.61. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $234.29.

IQVIA (NYSE:IQV) last released its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The firm had revenue of $4.10 billion during the quarter, compared to the consensus estimate of $4.07 billion. During the same period in the prior year, the company posted $2.84 EPS. The company’s revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

IQV has been the subject of several research reports. Robert W. Baird set a $258.00 price objective on shares of IQVIA and gave the stock an “outperform” rating in a research report on Wednesday, October 29th. Cowen cut IQVIA from a “buy” rating to a “hold” rating in a report on Monday, November 3rd. Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, December 6th. Truist Financial reiterated a “buy” rating and set a $265.00 price objective (up previously from $235.00) on shares of IQVIA in a research report on Wednesday, October 29th. Finally, Stifel Nicolaus boosted their target price on shares of IQVIA from $234.00 to $254.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $243.59.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.